InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: Carboat post# 270997

Saturday, 08/27/2016 6:00:32 AM

Saturday, August 27, 2016 6:00:32 AM

Post# of 345746
False. Incorrect. The proxy clearly states that the BOD can completely dismiss the RS proposal. It will all depend upon market conditions, stock price and other factors..possibly if the lid is removed and Roche/Novartis has quite the relationship. Maybe Roche is getting ticked off about the idea that Novartis wants all ingredients of an IO pipeline inhouse under one roof and can you imagine if PS Targeting is part of it : )

Next....of course Roche did not like Novartis picking up 33% of Roche stock and imagine 1/3 of Roche transferred over to Novartis friendly hands. Novartis always wanted to partner with Roche in years past and if Roche (assuming they are the ones that own quite a bit of PPHM in separate off shore family accounts...) could easily use that power to keep a lid on PPHM are now realizing that Peregrine would RS in a heartbeat to possibly remove the chokehold and appease Novartis whom may not want to jump on board with Peregrine all while having the nemisis of Roche looming and blindly controlling from a distance....

Well...things can happen quickly and would it ever reach the point where Roche would now make a deal with Novartis and all in hopes to have that PS Targeting advantage.....hmmmm

Calico... You don't even want to join this catfight.... It seems some will stop at nothing to control PS Targeting

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News